TechnologyJ&J MedTech presents the first Ottava surgical robot clinical...

J&J MedTech presents the first Ottava surgical robot clinical cases

-

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric bypass procedure in Texas.
The system received FDA approval during the previous fall to initiate human trials, serving both laparoscopic procedures and open soft tissue surgeries, as well as hybrid surgery models. The debut of Ottava for human use was originally planned for late 2022 but was delayed due to the pandemic’s technical difficulties and operational disturbances.
The company revealed that successful completion of the current study will enable FDA de novo clearance for multiple general surgery procedures in the upper abdominal area, including gastric bypass and sleeve surgeries and small bowel resections, and hiatal hernia repairs.

The system received testing during the trial at Memorial Hermann-Texas Medical Center through a Roux-en-Y procedure, which developed a smaller stomach pouch and directed it to the small intestine.
Hani Abouhalka from J&J MedTech expressed pride in the program achieving this vital robotic surgery point as group surgery chairman in his statement. The advanced surgical technology portfolio from our company includes Ottava as its core product, which is designed to transform all surgical operations.
The JJ product description states that Ottava works within standard operating room spaces and includes robotic arms that attach to a movable table, which can be stored below the floor. Operational instruments throughout Ottava’s setup belong exclusively to Ethicon, J&J’s surgical instruments division.
The patient table integrates with robotic arms to dynamically reposition patients while the operation continues uninterrupted.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 Reasons Omnichannel Engagement Still Falls Short in Healthcare

Executive Summary Omnichannel engagement has become one of the most important strategic priorities across healthcare, pharmaceuticals, medical technology, and life...

After FDA takes firm stance on safety hazards, Fulcrum discontinues the SCD program and explores other options

After the FDA's tough stance on the modality following the recent withdrawal of Ipsen's Tazverik from the U.S. market,...

Subtle Medical Gets $33M Series C Funding, Appoints New CEO

Radiology departments at hospitals continue to face significant capacity constraints, while imaging procedures often remain a frustrating experience for...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you